FIGO 2018 Stage IB2 (> 2 to ≤4cm) Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery (CoNteSSa) / Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility

Summary

This study will include patients with invasive cervical cancer that wish to keep their fertility as much as possible in the future after treatment. Patients who receive surgery alone may experience long-term side effects including infertility. The purpose of this research study is to determine whether giving neo-adjuvant chemotherapy prior to surgery can maintain fertility in patients with invasive cervical cancer. The neo-adjuvant chemotherapy will consist of a platinum-based chemotherapy drug cisplatin or carboplatin, with a chemotherapy drug called paclitaxel. These are common chemotherapy drugs used in the treatment of women with cervical cancers.

Description

Eligibility

Age range

18–40 years

Sex

Female

Healthy volunteers

No

Interventions

• Drug
  Cisplatin

  Cisplatin is an antineoplastic agent that is commonly used for the treatment of cervical cancer.

• Drug
  Carboplatin

  Carboplatin is an antineoplastic agent that is commonly used for the treatment of cervical cancer.

• Drug
  Paclitaxel

  Paclitaxel is an antineoplastic agent that is commonly used in combination with cisplatin or carboplatin for the treatment of cervical cancer.

• Procedure
  Trachelectomy

  Surgery to remove the cervix but keep the uterus intact.

Locations (4)